

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5831890

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ANTONIOS ZOGRAFOS	09/09/2019
LAURIE M. CLOTILDE	09/06/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SAFETRACES, INC.
<b>Street Address:</b>	6111 JOHNSON COURT, SUITE 200
<b>City:</b>	PLEASANTON
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94588
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16554294
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(206)757-7700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2066223150
<b>Email:</b>	patentdocket@dwt.com, robbrownstein@dwt.com
<b>Correspondent Name:</b>	DAVIS WRIGHT TREMAINE LLP
<b>Address Line 1:</b>	920 FIFTH AVENUE, SUITE 3300
<b>Address Line 4:</b>	SEATTLE, WASHINGTON 98104
<b>ATTORNEY DOCKET NUMBER:</b>	0105863-005US0
<b>NAME OF SUBMITTER:</b>	PHILIP H. ALBERT
<b>SIGNATURE:</b>	/Philip H. Albert/
<b>DATE SIGNED:</b>	11/21/2019
<b>Total Attachments: 2</b>	
source=2018-08-28-Assignment signed- 0105863-005US0#page1.tif	
source=2018-08-28-Assignment signed- 0105863-005US0#page2.tif	


**ASSIGNMENT - (PATENT APPLICATION)**

Title: PRODUCT TRACKING AND RATING SYSTEM USING DNA TAGS  
App. Serial No.: 16/554,294  
Filing Date: August 28, 2019  
Inventor(s): Antonios Zografos; Laurie M. Clotilde  
Assignee: SafeTraces, Inc., a Delaware corporation, having a principal place of  
business at 6111 Johnson Court, Suite 200, Pleasanton, California 94588

1. We/I, the above-named and undersigned inventor(s), have invented certain inventions and improvements disclosed in the above-referenced patent (provisional or non-provisional) application or design patent application.
2. We/I, for good and valuable consideration, the receipt and sufficiency of which we/I hereby acknowledge, agree to, and hereby do, assign, transfer, convey, and sell and/or hereby confirm that we/I have assigned, transferred, conveyed, and sold to Assignee the entire right, title, and interest in and to:
  - (a) the above-referenced patent application and all patent applications based in whole or in part upon the above-referenced patent application, including, without limitation, applications that are a provisional, non-provisional, counterpart, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, or extension, as well as non-U.S. patent applications or applications for other rights based in whole or in part on the above-referenced patent application;
  - (b) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, and extensions) that are granted or issued upon, or that claim priority to, any applications described in (a) above, that disclose or claim intellectual property described in (b) above, or that result from reexamination, post-grant review, inter partes review or supplemental examination of any applications described in (a) above;
  - (d) the right to claim priority to the above-referenced patent application as well as to any and all applications described in (a) above, including all rights of priority under the Paris Convention, other international conventions, treaties, or agreements; and
  - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. § 154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

3. We/I authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 2 above.
4. We/I agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 2 above and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
5. We/I agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us/me, as well as our/my heirs, legal representatives, and assigns.
6. The right, title and interest are to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon.
7. We/I promise and affirm that we/I have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
8. If the application number and filing date are blank above in this Assignment, we/I authorize Davis Wright Tremaine LLP to insert the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our/my signature.

Signature:  \_\_\_\_\_ Date: 9/9/2019  
Name: Antonios Zografos

Signature:  \_\_\_\_\_ Date: 6Sep2019  
Name: Laurie M. Clotilde